Across TCGA pan-cancer cohorts, RNY1P16 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of RNY1P16’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where RNY1P16 RNA is repressed in tumor relative to normal tissue. In most cancer types RNY1P16 is over-expressed in tumor, although a few such as LUAD show the opposite, repressed pattern.

LUAD, THCA, and LIHC are the cancer types where RNY1P16 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNY1P16 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	III,IV	−0.848	.013	3	view →
THCA	All	All	+0.526	.004	2	view →
LIHC	Male	All	+0.386	.002	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: RNY1P16 RNA expression & survival · all RNY1P16 data types